Tuesday, September 17, 2024, 11:00 AM – 3:30 PM CDT
4V. Bio-Hazardous Drugs
Patrick Conley, MS, CBSP(ABSA), NREMT, Merrick and Company, Keller, TX
The anticipated implementation of United States Pharmacopeia (USP) 800 in healthcare created a new resolve to conduct thorough risk assessments of healthcare formularies. The role of this assessment was to identify the hazards posed by these drugs, to evaluate the exposure risks associated with these hazards, and to determine the potential health consequences of both acute and chronic exposure. Most healthcare facilities that conducted these risk assessments utilized a risk matrix that incorporated criteria commonly used in toxicology to evaluate exposure to chemicals. As the pharmaceutical industry quickly turns to novel biologics to treat and/or correct disease, a risk assessment of the biological hazards associated with these novel biologics is warranted. This course will provide information on these biologics; explore the known and anticipated biological properties of each; discuss the potential these biologics have to cause infections, to be shed, to contaminate the environment, and to be transmitted to others; and will cover the pertinent controls needed to contain these biologics, to prevent inadvertent exposure to these materials, to remove them from the environment, and to ensure staff and patients are appropriately educated.
Objectives:
- Define a hazardous drug and a hazardous biologic
- Recognize the hazards, exposure risks, and health consequences posed by these hazardous drugs and hazardous biologics
- Describe pertinent healthcare and pharmacy standards concerning hazardous drugs and hazardous biologics
Suggested Background: Risk Assessment, Virology/Viral Vectors
Target Audience: All Safety Professionals, All Biosafety Professionals
Audience Level: Basic
Course Length: 4 hours (one 4-hour live session with a 30-minute break)
This course has been approved for 0.5 CM points toward RBP/CBSP recertification. *ABSA International is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. This course is approved for 4.50 P.A.C.E.® contact hours. The links to the various invitations for the course will be unique to the user and cannot be shared. The links to the various invitations for the course will be unique to the user and cannot be shared. The links are for single, individual use only. If more than one occurrence of an individual’s name is on the Zoom attendee list or a name not of the roster, all instances will be removed from the webinar with no refund. The webinar and its associated links are for single, individual use only.
To obtain the ABSA member rate, the participant will need to be an ABSA member in the year in which the training is offered. Confirmed, paid participants will be sent detailed information regarding the course within a few days prior to the course. Substitutions allowed with notice by 8/20/2024. There is a 15% processing fee for cancellations by 8/27/2024. Cancellations between 8/27/2024 and 9/03/2024 will be refunded at 50% of the course fee. No refunds after 9/03/2024.
